MaxCyte Inc (LON:MXCT)‘s stock had its “buy” rating reiterated by research analysts at Panmure Gordon in a research report issued on Tuesday. They presently have a GBX 338 ($4.56) target price on the stock. Panmure Gordon’s target price would suggest a potential upside of 36.57% from the company’s previous close.

MaxCyte (LON:MXCT) opened at 247.50 on Tuesday. The firm’s market cap is GBX 107.76 million. The company has a 50-day moving average of GBX 245.88 and a 200 day moving average of GBX 258.22. MaxCyte has a 12-month low of GBX 83.00 and a 12-month high of GBX 305.00.

COPYRIGHT VIOLATION WARNING: “MaxCyte Inc (MXCT) Stock Rating Reaffirmed by Panmure Gordon” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at

MaxCyte Company Profile

MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.

Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with's FREE daily email newsletter.